278 related articles for article (PubMed ID: 23047001)
41. Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors.
Arfeen M; Bhagat S; Patel R; Prasad S; Roy I; Chakraborti AK; Bharatam PV
Eur J Med Chem; 2016 Oct; 121():727-736. PubMed ID: 27423119
[TBL] [Abstract][Full Text] [Related]
42. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.
Bertrand JA; Thieffine S; Vulpetti A; Cristiani C; Valsasina B; Knapp S; Kalisz HM; Flocco M
J Mol Biol; 2003 Oct; 333(2):393-407. PubMed ID: 14529625
[TBL] [Abstract][Full Text] [Related]
43. Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamides as selective GSK-3 inhibitors.
Koryakova AG; Ivanenkov YA; Ryzhova EA; Bulanova EA; Karapetian RN; Mikitas OV; Katrukha EA; Kazey VI; Okun I; Kravchenko DV; Lavrovsky YV; Korzinov OM; Ivachtchenko AV
Bioorg Med Chem Lett; 2008 Jun; 18(12):3661-6. PubMed ID: 18502121
[TBL] [Abstract][Full Text] [Related]
44. Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
Wang Y; Dou X; Jiang L; Jin H; Zhang L; Zhang L; Liu Z
Eur J Med Chem; 2019 Jun; 171():221-234. PubMed ID: 30925338
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and biological evaluation of 3-benzisoxazolyl-4-indolylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3β.
Ye Q; Li M; Zhou Y; Pang T; Xu L; Cao J; Han L; Li Y; Wang W; Gao J; Li J
Molecules; 2013 May; 18(5):5498-516. PubMed ID: 23669633
[TBL] [Abstract][Full Text] [Related]
46. Design, Synthesis and in Vitro Tumor Cytotoxicity Evaluation of 3,5-Diamino-N-substituted Benzamide Derivatives as Novel GSK-3β Small Molecule Inhibitors.
Zhou Y; Zhang L; Fu X; Jiang Z; Tong R; Shi J; Li J; Zhong L
Chem Biodivers; 2019 Sep; 16(9):e1900304. PubMed ID: 31338947
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
Ye Q; Xu G; Lv D; Cheng Z; Li J; Hu Y
Bioorg Med Chem; 2009 Jul; 17(13):4302-12. PubMed ID: 19481464
[TBL] [Abstract][Full Text] [Related]
48. Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching.
Conde S; Pérez DI; Martínez A; Perez C; Moreno FJ
J Med Chem; 2003 Oct; 46(22):4631-3. PubMed ID: 14561081
[TBL] [Abstract][Full Text] [Related]
49. Concise synthesis and CDK/GSK inhibitory activity of the missing 9-azapaullones.
Power DP; Lozach O; Meijer L; Grayson DH; Connon SJ
Bioorg Med Chem Lett; 2010 Aug; 20(16):4940-4. PubMed ID: 20621478
[TBL] [Abstract][Full Text] [Related]
50. Identification of small molecules that inhibit GSK-3beta through virtual screening.
Kang NS; Lee GN; Kim CH; Bae MA; Kim I; Cho YS
Bioorg Med Chem Lett; 2009 Jan; 19(2):533-7. PubMed ID: 19081248
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
Kuo GH; Prouty C; DeAngelis A; Shen L; O'Neill DJ; Shah C; Connolly PJ; Murray WV; Conway BR; Cheung P; Westover L; Xu JZ; Look RA; Demarest KT; Emanuel S; Middleton SA; Jolliffe L; Beavers MP; Chen X
J Med Chem; 2003 Sep; 46(19):4021-31. PubMed ID: 12954055
[TBL] [Abstract][Full Text] [Related]
52. Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.
Usui Y; Uehara F; Hiki S; Watanabe K; Tanaka H; Shouda A; Yokoshima S; Aritomo K; Adachi T; Fukunaga K; Sunada S; Nabeno M; Saito KI; Eguchi JI; Yamagami K; Asano S; Tanaka S; Yuki S; Yoshii N; Fujimura M; Horikawa T
Bioorg Med Chem Lett; 2017 Aug; 27(16):3726-3732. PubMed ID: 28712708
[TBL] [Abstract][Full Text] [Related]
53. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
[TBL] [Abstract][Full Text] [Related]
54. Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
Vadivelan S; Sinha BN; Tajne S; Jagarlapudi SA
Eur J Med Chem; 2009 Jun; 44(6):2361-71. PubMed ID: 18929433
[TBL] [Abstract][Full Text] [Related]
55. 2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability.
Saitoh M; Kunitomo J; Kimura E; Iwashita H; Uno Y; Onishi T; Uchiyama N; Kawamoto T; Tanaka T; Mol CD; Dougan DR; Textor GP; Snell GP; Takizawa M; Itoh F; Kori M
J Med Chem; 2009 Oct; 52(20):6270-86. PubMed ID: 19775160
[TBL] [Abstract][Full Text] [Related]
56. Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core.
Sivaprakasam P; Han X; Civiello RL; Jacutin-Porte S; Kish K; Pokross M; Lewis HA; Ahmed N; Szapiel N; Newitt JA; Baldwin ET; Xiao H; Krause CM; Park H; Nophsker M; Lippy JS; Burton CR; Langley DR; Macor JE; Dubowchik GM
Bioorg Med Chem Lett; 2015 May; 25(9):1856-63. PubMed ID: 25845281
[TBL] [Abstract][Full Text] [Related]
57. Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review.
Xu M; Wang SL; Zhu L; Wu PY; Dai WB; Rakesh KP
Eur J Med Chem; 2019 Feb; 164():448-470. PubMed ID: 30616053
[TBL] [Abstract][Full Text] [Related]
58. In silico deconstruction of ATP-competitive inhibitors of glycogen synthase kinase-3β.
Bisignano P; Lambruschini C; Bicego M; Murino V; Favia AD; Cavalli A
J Chem Inf Model; 2012 Dec; 52(12):3233-44. PubMed ID: 23198830
[TBL] [Abstract][Full Text] [Related]
59. 2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors.
Fukunaga K; Uehara F; Aritomo K; Shoda A; Hiki S; Okuyama M; Usui Y; Watanabe K; Yamakoshi K; Kohara T; Hanano T; Tanaka H; Tsuchiya S; Sunada S; Saito K; Eguchi J; Yuki S; Asano S; Tanaka S; Mori A; Yamagami K; Baba H; Horikawa T; Fujimura M
Bioorg Med Chem Lett; 2013 Dec; 23(24):6933-7. PubMed ID: 24176395
[TBL] [Abstract][Full Text] [Related]
60. 6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors.
Uehara F; Shoda A; Aritomo K; Fukunaga K; Watanabe K; Ando R; Shinoda M; Ueno H; Kubodera H; Sunada S; Saito K; Kaji T; Asano S; Eguchi J; Yuki S; Tanaka S; Yoneyama Y; Niwa T
Bioorg Med Chem Lett; 2013 Dec; 23(24):6928-32. PubMed ID: 24094818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
